Title : Impact of Tigecycline's MIC in the Outcome of Critically Ill Patients with Carbapenemase-Producing Klebsiella pneumoniae Bacteraemia Treated with Tigecycline Monotherapy-Validation of 2019's EUCAST Proposed Breakpoint Changes.

Pub. Date : 2020 Nov 19

PMID : 33228012






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 BACKGROUND: Tigecycline is a therapeutic option for carbapenemase-producing Klebsiella pneumoniae (CP-Kp). Tigecycline phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 alpha Homo sapiens
2 CONCLUSION: Tigecycline monotherapy was as efficacious as other antimicrobials in the treatment of bloodstream infections due to CP-Kp isolates with a tigecycline"s MIC <= 0.5 mg/L. Tigecycline phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 alpha Homo sapiens
3 CONCLUSION: Tigecycline monotherapy was as efficacious as other antimicrobials in the treatment of bloodstream infections due to CP-Kp isolates with a tigecycline"s MIC <= 0.5 mg/L. Tigecycline phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 alpha Homo sapiens